Back

Efficacy and safety of sacubitril/valsartan in the management of heart failure with reduced ejection fraction and chronic kidney disease: a systematic review and meta-analysis

10 May 2026 (11:30 - 12:15)
Organised by: Logo
Congress Presentation Part of: Advanced pharmacotherapy in complex heart failure scenarios Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Bruno Chan Chin

University Hospital Limerick, Limerick (Ireland)

6 More presentations in this session

Presentation thumbnail
Efficacy and safety of sacubitril-valsartan versus enalapril in patients with heart failure due to Chagas cardiomyopathy: a systematic review and meta-analysis
Doctor B. Aziri (Sarajevo, BA)
Abstract Slides Video
Presentation thumbnail
Improved subgroup treatment effect estimation in heart failure trials using Bayesian hierarchical shrinkage models
Doctor A. Henderson (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Sacubitril/valsartan, initial dip in estimated glomerular filtration rate, and clinical outcomes in patients with heart failure
Doctor M. Manabe (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Guideline directed medical therapy in patients with heart failure with reduced ejection fraction undergoing renal replacement therapy: real world experience from a specialized cardiorenal unit
Doctor S. Ruiz Bustillo (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Effect of sacubitril/valsartan and SGLT2 inhibitors on echocardiographic response and clinical outcomes after cardiac resynchronization therapy: insights from a real-world cohort
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Advanced pharmacotherapy in complex heart failure scenarios

The Event

Event poster

Heart Failure 2026

10 May 2026 11:30 CET
You may be interested in
thumbnail
Congress Presentation
Effects of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and an eGFR below 30 ml/min/1.73 m2
thumbnail
Congress Presentation
Real world data using sacubitril/valsartan in CKD stage 4 and 5 is associated with improved ejection fraction and may have renoprotective effects.
thumbnail
Congress Presentation
Clinical features and treatment of patients with heart failure and advanced chronic kidney disease

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources